Adial Pharmaceuticals (ADIL) Total Non-Current Liabilities (2022 - 2025)
Adial Pharmaceuticals (ADIL) posted Total Non-Current Liabilities of $6.9 million for Q4 2025, up 187.89% sequentially from $2.4 million in Q2 2025, and up 643.78% YoY from $929156.0 in Q4 2024.
Adial Pharmaceuticals (ADIL) Total Non-Current Liabilities (2022 - 2025) Analysis & Trends
Adial Pharmaceuticals has reported Total Non-Current Liabilities for 4 years, with the latest figure at $6.9 million in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 643.78% year-over-year to $6.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.9 million (up 643.78% YoY) and the FY2025 annual result came in at $6.9 million, up 643.78% from the prior year.
- Total Non-Current Liabilities advanced to $6.9 million in Q4 2025 per ADIL's latest filing, from $2.4 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $6.9 million in Q4 2025 and troughed at $302286.0 in Q1 2024.
- A 4-year average of $1.7 million and a median of $929156.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities tumbled 68.52% in 2023, then soared 643.78% in 2025.
- Over 4 years, Total Non-Current Liabilities stood at $1.8 million in 2022, then sank by 68.52% to $563785.0 in 2023, then surged by 64.81% to $929156.0 in 2024, then jumped by 643.78% to $6.9 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $6.9 million, $2.4 million, and $2.0 million for Q4 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 9.32 Bn |
| 10 | Adial Pharmaceuticals | 27.59 Mn | 27.59 Mn | - | 5.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.91 Mn |
| Jun 30, 2025 | 2.40 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 929,156.00 |
| Sep 30, 2024 | 929,156.00 |
| Jun 30, 2024 | 454,905.00 |
| Mar 31, 2024 | 302,286.00 |
| Dec 31, 2023 | 563,785.00 |
| Sep 30, 2023 | 521,592.00 |
| Dec 31, 2022 | 1.79 Mn |